News | January 21, 2026
Tatva Chintan Pharma Chem posts consolidated Q3 FY26 at Rs. 15.16 Cr
Tatva Chintan Pharma Chem has reported total income of Rs. 133.06 crore during the period ended December 31, 2025
Tatva Chintan Pharma Chem has reported total income of Rs. 133.06 crore during the period ended December 31, 2025
The injectable borofalan (10B), developed by CNNC Headway—a subsidiary of China Isotope & Radiation Corporation (CIRC) under the China National Nuclear Corporation (CNNC)—has officially entered Phase I clinical trials
The company recorded revenue of Rs. 1,065 crore in the third quarter of FY26
Dr. Reddy’s Olopatadine Hydrochloride Ophthalmic Solution USP, 0.7% is an antihistamine eye drop, indicated for the temporary relief of itchy eyes due to pollen, ragweed, grass, animal hair and dander
The new assets expand Biocon Biologics’ already robust oncology portfolio, which now includes 17 cancer therapies
Rajdeep is an accomplished business leader with a strong techno-commercial background in the healthcare and diagnostic sector
Syrma Johari is a globally recognised medical device engineering and manufacturing organisation
Dr. Bandichhor brings nearly two decades of experience from Dr. Reddy's Laboratories
Singh previously served as Head of IT (Development and Manufacturing Services) at Syngene International Limited, Lead of IT Manufacturing at UPL, and AGM at The Hi-Tech Gears
The cancellation underscores the regulator’s strict stance against misleading cosmetic claims
Subscribe To Our Newsletter & Stay Updated
